Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 21, 2025
Editor's Commentary
No causal biology without diversity: a Perspective
As human data are poised to deliver causal targets and more precise interventions, caving to anti-DEI rhetoric
BioCentury | Feb 20, 2025
Emerging Company Profile
Switch: Precision siRNA knockdown
San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
BioCentury | Dec 31, 2024
Management Tracks
Casdin to succeed Cox at Epirium
Plus: van Tilburg takes the helm at Renovaro and updates from Medicilon, Applied, Neurocentrx and more
BioCentury | Oct 28, 2024
Emerging Company Profile
Red Queen: A new approach to viral fusion proteins
Apple Tree Partners launches infectious disease company with stapled lipopeptide tech for blocking viral fusion
BioCentury | Oct 24, 2024
Product Development
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals
Therapies aim to enhance lysosomal function to clear cholesterol and glycosphingolipids, mostly via small molecules
BioCentury | Oct 10, 2024
Discovery & Translation
Science Spotlight: As miRNAs get Nobel Prize, targeting advances continue
BioCentury’s roundup of translational innovation also features Vedanta’s solution to GI infection, Takeda’s exon-skipping delivery tech, and more
Items per page:
1 - 10 of 2346